Sugi Predict

Sugi Predict / Targets / CDK15

CDK15

Cyclin-dependent kinase 15 · Q96Q40 · CDK15 on Sugi Atlas →

2,747 patent compounds predicted against CDK15, 2,391 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Rg-547 Rg-547 (SCHEMBL2397067) 1.00 1/20
At-7519 At-7519 (SCHEMBL21134171) 1.00 1/20
SCHEMBL3522526 SCHEMBL3522526 0.91 1/20
SCHEMBL3522463 SCHEMBL3522463 0.89 1/20
SCHEMBL4350447 SCHEMBL4350447 0.87 1/20
SCHEMBL4354399 SCHEMBL4354399 0.86 1/20
SCHEMBL4355436 SCHEMBL4355436 0.86 1/20
SCHEMBL4365008 SCHEMBL4365008 0.85 1/20
SCHEMBL14723511 SCHEMBL14723511 0.85 1/20
SCHEMBL3521770 SCHEMBL3521770 0.84 1/20
SCHEMBL4348141 SCHEMBL4348141 0.84 1/20
SCHEMBL4352814 SCHEMBL4352814 0.82 1/20
SCHEMBL4355426 SCHEMBL4355426 0.81 1/20
SCHEMBL4360093 SCHEMBL4360093 0.81 1/20
SCHEMBL4349013 SCHEMBL4349013 0.81 1/20
SCHEMBL3520853 SCHEMBL3520853 0.80 1/20
SCHEMBL4348415 SCHEMBL4348415 0.80 1/20
SCHEMBL5393063 SCHEMBL5393063 0.80 1/20
SCHEMBL4352687 SCHEMBL4352687 0.79 1/20
SCHEMBL4352714 SCHEMBL4352714 0.79 1/20

Clinical trials — most relevant to CDK15 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors PHASE1/PHASE2COMPLETED
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy PHASE2COMPLETED
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors PHASE1/PHASE2COMPLETED
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients PHASE2COMPLETED
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
RP-6306 in Patients With Advanced Cancer PHASE2COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia PHASE1WITHDRAWN
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas PHASE1COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers PHASE1COMPLETED
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors PHASE1COMPLETED
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma PHASE1WITHDRAWN
The SONImage Study nanACTIVE_NOT_RECRUITING
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK15 binder may also engage these)

ProteinNameSimilarity
Q3V3A1 — 1.000 Q3V3A1 →
Q1RLU9 — 0.992 Q1RLU9 →
B0VXL7 — 0.988 B0VXL7 →
C0RW22 — 0.987 C0RW22 →
CDK18 Cyclin-dependent kinase 18 0.987 landscape →
MKNK1 MAP kinase-interacting serine/threonine-protein kinase 1 0.987 landscape →
O35832 — 0.986 O35832 →
Q5RD01 — 0.986 Q5RD01 →
PHKG2 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform 0.985 landscape →
B0VXE8 — 0.984 B0VXE8 →
Q04899 — 0.983 Q04899 →
O19111 — 0.983 O19111 →
Q8VZD5 — 0.983 Q8VZD5 →
A4IIW7 — 0.983 A4IIW7 →
Q6DJM7 — 0.983 Q6DJM7 →
Q9Z2A6 — 0.983 Q9Z2A6 →
P51138 — 0.982 P51138 →
O35495 — 0.982 O35495 →
Q84SN3 — 0.982 Q84SN3 →
DYRK4 Dual specificity tyrosine-phosphorylation-regulated kinase 4 0.982 landscape →
CDK14 Cyclin-dependent kinase 14 0.982 landscape →
P43294 — 0.982 P43294 →
Q3ULB5 — 0.982 Q3ULB5 →
JAK3 Tyrosine-protein kinase JAK3 0.982 landscape →
B6A7Q3 — 0.982 B6A7Q3 →
Q91VB2 — 0.981 Q91VB2 →
O80673 — 0.981 O80673 →
P43289 — 0.981 P43289 →
O08605 — 0.980 O08605 →
Q9DB30 — 0.980 Q9DB30 →